Abstract
Diffuse large B-cell lymphoma is a malignant neoplasm of the lymphoid system and represents the majority cases of non-Hodgkin lymphomas. Nevertheless, it is a low-rate event in the head and neck region, especially as a primary occurrence. This is a case report of a primary extranodal diffuse large B-cell lymphoma in the mandible of a 52-year-old male patient who had no previous neoplasm history. Clinical examination and image examinations evidenced an asymptomatic singular intraosseous lesion in the mandibular bone measuring 5 cm, presenting one-and-a-half-year evolution. Odontogenic myxoma was clinical diagnostic hypothesis, and an incisional biopsy was performed. Microscopy was compatible with malignant neoplasm and immunohistochemical analysis was positive for CD20, PAX5, CD3, CD4, and CD10 markers, concluding the diagnosis of diffuse large B-cell lymphoma. The patient was treated with 4 cycles of rituximab plus cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), and prednisone chemotherapy protocol. He responded very positively to the treatment and is still under follow-up. Diffuse large B-cell lymphoma is a malignant neoplasm of the lymphoid system and represents the majority cases of non-Hodgkin lymphomas. Nevertheless, it is a low-rate event in the head and neck region, especially as a primary occurrence. This is a case report of a primary extranodal diffuse large B-cell lymphoma in the mandible of a 52-year-old male patient who had no previous neoplasm history. Clinical examination and image examinations evidenced an asymptomatic singular intraosseous lesion in the mandibular bone measuring 5 cm, presenting one-and-a-half-year evolution. Odontogenic myxoma was clinical diagnostic hypothesis, and an incisional biopsy was performed. Microscopy was compatible with malignant neoplasm and immunohistochemical analysis was positive for CD20, PAX5, CD3, CD4, and CD10 markers, concluding the diagnosis of diffuse large B-cell lymphoma. The patient was treated with 4 cycles of rituximab plus cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), and prednisone chemotherapy protocol. He responded very positively to the treatment and is still under follow-up.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
